Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
- Friday, August 18, 2023, 7:10
- PR Newswire
- Add a comment
HONG KONG, Aug. 18, 2023 /PRNewswire/ — Akeso Inc. (“Akeso”, 9926. HK) announced today that the first patient has been dosed in a head-to-head phase III trial of ivonescimab, a potential first-in-class investigational PD-1/VEGF bi-specific antibody discovered by Akeso. The Phase III…
About the Author
admin has written 20663 stories on this site.